Program
JNJ-99220732
A development code.
Its studies are mostly in Neoplasms, led by Johnson & Johnson.
Furthest: phase 1, since Nov 12, 20261 company-led study, 1 open or runningNext primary completion: Jan 5, 2029 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 11 open or running | phase 1since Nov 12, 2026 | Nov 12, 2026 | Jan 5, 2029phase 1 · NCT07943078 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 12, 2026First study: phase 1 study in NeoplasmsFirst studyNCT07943078 · 200 planned
Ahead
- Jan 5, 2029Primary completion: phase 1 study in NeoplasmsNCT07943078
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07943078Neoplasms | 1 | Not yet recruiting | Jan 5, 2029 | 200 |
How it is read
Names in the registry
- “JNJ-99220732”, 1 entry
Codes read as this program: JNJ99220732.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.